SCHEMBL6434803

SCHEMBL6434803

N=C(N)N(Cl)c1cncc2cc(S(=O)(=O)N3CCC[C@@H]3C(=O)NCCO)ccc12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
HPGD P15428 1/20 0.44
PLAU P00749 3/20 0.40
FKBP1A P62942 3/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCR4 P51679 2/20 0.39
TP53 P04637 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
RECQL P46063 1/20 0.39
LGMN Q99538 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432552 0.91 LMNA (0.43) LMNAHPGDFKBP1AKDM4ETP53
SCHEMBL7412033 0.91 LMNA (0.43) LMNAHPGDFKBP1AKDM4ETP53
SCHEMBL7380961 0.87 PLAU (0.52) LMNAPLAUKDM4ECCR4HSD17B10
SCHEMBL7365360 0.86 PLAU (0.52) LMNAPLAUKDM4EALDH1A1CCR4
Hydrochloric Acid SCHEMBL7366138 0.86 PLAU (0.51) LMNAPLAUKDM4EALDH1A1CCR4
Hydrochloric Acid SCHEMBL7368606 0.86 PLAU (0.51) LMNAPLAUKDM4EALDH1A1CCR4
SCHEMBL6450526 0.84 CCR4 (0.39) LMNAPLAUKDM4ECCR4RECQL
SCHEMBL7370376 0.84 PLAU (0.53) PLAUKDM4EALDH1A1CCR4HSD17B10
Hydrochloric Acid SCHEMBL7369167 0.83 PLAU (0.52) PLAUKDM4EALDH1A1CCR4HSD17B10
SCHEMBL7368857 0.83 LMNA (0.45) LMNAHPGDPLAUFKBP1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 LMNA 1451/4885HPGD 913/4885PLAU 119/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 LMNA 1451/4885HPGD 913/4885PLAU 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.